Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2002;105:1989-1994
Published online before print April 1, 2002, doi: 10.1161/01.CIR.0000014968.54967.D3
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
105/16/1989    most recent
01.CIR.0000014968.54967.D3v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roth, D. M.
Right arrow Articles by Hammond, H. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roth, D. M.
Right arrow Articles by Hammond, H. K.
Related Collections
Right arrow Animal models of human disease
Right arrow Gene therapy

(Circulation. 2002;105:1989.)
© 2002 American Heart Association, Inc.


Basic Science Reports

Adenylyl Cyclase Increases Survival in Cardiomyopathy

David M. Roth, PhD MD; Hamed Bayat, MD; Jeffrey D. Drumm, BS; Mei Hua Gao, PhD; James S. Swaney, MS; Aziz Ander, BS; H. Kirk Hammond, MD

From the VA San Diego Healthcare System (D.M.R., H.B., J.S.S., A.A., H.K.H.); Departments of Anesthesiology (D.M.R.) and Medicine (H.B., H.K.H.), University of California, San Diego; and Collateral Therapeutics Incorporated (J.D.D., H.M.G.), San Diego, Calif.

Correspondence to H. Kirk Hammond, MD (111-A), VA San Diego Healthcare System, 3350 La Jolla Village Dr, San Diego, CA 92161. E-mail khammond{at}ucsd.edu

Background To test the hypothesis that increased cardiac adenylyl cyclase type VI (ACVI) content, which results in increased cAMP generation, would increase survival in cardiomyopathy, we crossbred mice with Gq-associated cardiomyopathy and those with cardiac-directed expression of ACVI. We also assessed myocardial hypertrophy after prolonged cardiac expression of Gq versus coexpression of Gq and ACVI.

Methods and Results Three experimental groups, Gq/AC (double positive), Gq, and control (double negative), were studied. Survival was increased by cardiac-directed expression of ACVI (P<0.0001), and Gq/AC mice had survival rates indistinguishable from control mice. Myocardial hypertrophy developed in older Gq mice but was abrogated by cardiac expression of ACVI, as documented by the ratio of ventricular weight to tibial length (Gq, 11.93±0.99 mg/mm, n=11; Gq/AC, 8.00±0.73 mg/mm, n=9; P<0.01) and by left ventricular cardiac myocyte size (Gq, 2800±254 µm2, n=4; Gq/AC, 1721±166 µm2, n=5; P<0.01). Hearts of Gq mice were dilated, and function was impaired. Concurrent expression of AC reduced end-diastolic diameter (Gq, 4.20±0.15 mm, n=12; Gq/AC, 3.68±0.12 mm, n=7; P<0.05) and increased fractional shortening (Gq, 32±1%, n=12; Gq/AC, 41±2%, n=7; P<0.001). Cardiac myocytes from Gq/AC mice showed increased forskolin-stimulated cAMP production (Gq, 3.8±1.3 fmol/cell, n=5; Gq/AC, 10.7±2.6 fmol/cell, n=6; P<0.02), documenting increased AC function.

Conclusions Cardiac-directed expression of ACVI restores myocyte AC function, improves heart function, increases cAMP generation, abrogates myocardial hypertrophy, and increases survival in Gq cardiomyopathy.


Key Words: receptors, adrenergic, beta • heart failure • myocytes




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
A. El-Armouche, K. Wittkopper, F. Degenhardt, F. Weinberger, M. Didie, I. Melnychenko, M. Grimm, M. Peeck, W. H. Zimmermann, B. Unsold, et al.
Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy
Cardiovasc Res, December 1, 2008; 80(3): 396 - 406.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. H. Gao, T. Tang, T. Guo, A. Miyanohara, T. Yajima, K. Pestonjamasp, J. R. Feramisco, and H. K. Hammond
Adenylyl Cyclase Type VI Increases Akt Activity and Phospholamban Phosphorylation in Cardiac Myocytes
J. Biol. Chem., November 28, 2008; 283(48): 33527 - 33535.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
L. E. Vinge, P. W. Raake, and W. J. Koch
Gene Therapy in Heart Failure
Circ. Res., June 20, 2008; 102(12): 1458 - 1470.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. C. Lai, T. Tang, M. H. Gao, M. Saito, T. Takahashi, D. M. Roth, and H. K. Hammond
Activation of Cardiac Adenylyl Cyclase Expression Increases Function of the Failing Ischemic Heart in Mice
J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1490 - 1497.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Gros, S. Van Uum, A. Hutchinson-Jaffe, Q. Ding, J. G. Pickering, R. A. Hegele, and R. D. Feldman
Increased Enzyme Activity and -Adrenergic Mediated Vasodilation in Subjects Expressing a Single-Nucleotide Variant of Human Adenylyl Cyclase 6
Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2657 - 2663.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. S. Swaney, H. H. Patel, U. Yokoyama, N. C. Lai, M. Spellman, P. A. Insel, and D. M. Roth
Adenylyl cyclase activity and function are decreased in rat cardiac fibroblasts after myocardial infarction
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3216 - H3220.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. Fischmeister, L. R.V. Castro, A. Abi-Gerges, F. Rochais, J. Jurevicius, J. Leroy, and G. Vandecasteele
Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases
Circ. Res., October 13, 2006; 99(8): 816 - 828.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Sastry, E. Arnold, H. Gurji, A. Iwasa, H. Bui, A. Hassankhani, H. H. Patel, J. R. Feramisco, D. M. Roth, N. C. Lai, et al.
Cardiac-Directed Expression of Adenylyl Cyclase VI Facilitates Atrioventricular Nodal Conduction
J. Am. Coll. Cardiol., August 1, 2006; 48(3): 559 - 565.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Colombo, S. Gatti, F. Turcatti, A. Sordi, L. R. Fassati, F. Bonino, J. M. Lipton, and A. Catania
Gene Expression Profiling Reveals Multiple Protective Influences of the Peptide {alpha}-Melanocyte-Stimulating Hormone in Experimental Heart Transplantation
J. Immunol., September 1, 2005; 175(5): 3391 - 3401.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. Ding, J.-i. Abe, H. Wei, Q. Huang, R. A. Walsh, C. A. Molina, A. Zhao, J. Sadoshima, B. C. Blaxall, B. C. Berk, et al.
Functional Role of Phosphodiesterase 3 in Cardiomyocyte Apoptosis: Implication in Heart Failure
Circulation, May 17, 2005; 111(19): 2469 - 2476.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Tang, M. H. Gao, D. M. Roth, T. Guo, and H. K. Hammond
Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy
Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H1906 - H1912.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. H. Gao, T. Tang, T. Guo, S. Q. Sun, J. R. Feramisco, and H. K. Hammond
Adenylyl Cyclase Type VI Gene Transfer Reduces Phospholamban Expression in Cardiac Myocytes via Activating Transcription Factor 3
J. Biol. Chem., September 10, 2004; 279(37): 38797 - 38802.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Sesti and R. A. Kloner
Gene Therapy in Congestive Heart Failure
Circulation, July 20, 2004; 110(3): 242 - 243.
[Full Text] [PDF]


Home page
CirculationHome page
N. C. Lai, D. M. Roth, M. H. Gao, T. Tang, N. Dalton, Y. Y. Lai, M. Spellman, P. Clopton, and H. K. Hammond
Intracoronary Adenovirus Encoding Adenylyl Cyclase VI Increases Left Ventricular Function in Heart Failure
Circulation, July 20, 2004; 110(3): 330 - 336.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. A Movsesian
Altered cAMP-mediated signalling and its role in the pathogenesis of dilated cardiomyopathy
Cardiovasc Res, June 1, 2004; 62(3): 450 - 459.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
L. G. MELO, A. S. PACHORI, D. KONG, M. GNECCHI, K. WANG, R. E. PRATT, and V. J. DZAU
Gene and cell-based therapies for heart disease
FASEB J, April 1, 2004; 18(6): 648 - 663.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. El-Armouche, O. Zolk, T. Rau, and T. Eschenhagen
Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure
Cardiovasc Res, December 1, 2003; 60(3): 478 - 487.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Okumura, G. Takagi, J.-i. Kawabe, G. Yang, M.-C. Lee, C. Hong, J. Liu, D. E. Vatner, J. Sadoshima, S. F. Vatner, et al.
Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload
PNAS, August 19, 2003; 100(17): 9986 - 9990.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Tomita, M. Nazmy, K. Kajimoto, G. Yehia, C. A. Molina, and J. Sadoshima
Inducible cAMP Early Repressor (ICER) Is a Negative-Feedback Regulator of Cardiac Hypertrophy and an Important Mediator of Cardiac Myocyte Apoptosis in Response to {beta}-Adrenergic Receptor Stimulation
Circ. Res., July 11, 2003; 93(1): 12 - 22.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
I. Sjaastad, J A. Wasserstrom, and O. M Sejersted
Heart failure - a challenge to our current concepts of excitation-contraction coupling
J. Physiol., January 1, 2003; 546(1): 33 - 47.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
P. Most, A. Remppis, and H. A Katus
Conditional AC type VI expression in the heart: relevant insights into function of inducible target gene expression
Cardiovasc Res, November 1, 2002; 56(2): 181 - 183.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. H. Gao, H. Bayat, D. M Roth, J. Yao Zhou, J. Drumm, J. Burhan, and H Kirk Hammond
Controlled expression of cardiac-directed adenylylcyclase type VI provides increased contractile function
Cardiovasc Res, November 1, 2002; 56(2): 197 - 204.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. M. Feldman
Adenylyl Cyclase: A New Target for Heart Failure Therapeutics
Circulation, April 23, 2002; 105(16): 1876 - 1878.
[Full Text] [PDF]